马尔堡病毒病的研究进展

doi:10.19871/j.cnki.xfcrbzz.2025.01.015

新发传染病电子杂志 ›› 2025, Vol. 10 ›› Issue (1): 77-81.doi: 10.19871/j.cnki.xfcrbzz.2025.01.015

马尔堡病毒病的研究进展

姚伟明, 王福祥, 张培燕, 卢洪洲

深圳市第三人民医院感染重症医学科/国家感染性疾病临床医学研究中心/南方科技大学第二附属医院,广东深圳 518112

收稿日期:2024-09-05 出版日期:2025-02-28 发布日期:2025-03-31
通讯作者: 卢洪洲,Email: luhongzhou@fudan.edu.cn
基金资助:
1.国家自然科学基金面上项目(82272318);2.深圳市医学研究专项资金资助项目（C2401021）;3.深圳市 “三名工程”医学团队项目(SZSM202311033);4.深圳市第三人民医院院内项目（G2022136）;5.深圳市重大新发突发传染病临床医学研究中心项目和深圳市高水平医院建设经费资助（LCYSSQ20220823091203007)

Research progress on Marburg virus disease

Yao Weiming, Wang Fuxiang, Zhang Peiyan, Lu Hongzhou

Department of Intensive Infectious Diseases， Shenzhen Third People's Hospital, National Clinical Research Center for Infectious Disease, The Second Affiliated Hospital of Southern University of Science and Technology, Guangdong Shenzhen 518112, China

Received:2024-09-05 Online:2025-02-28 Published:2025-03-31

摘要/Abstract

摘要： 马尔堡病毒自1967年在德国马尔堡、法兰克福和南斯拉夫疫情暴发中首次被发现以来,已在各大洲引发了多次高病死率疫情,主要集中在撒哈拉以南的非洲地区。该病毒是丝状病毒家族中的一员,感染者常出现严重的出血热,随后导致器官功能衰竭和死亡。马尔堡病毒病可在家庭或医院环境中进行人际传播,目前尚无有效的预防或治疗手段,但系统性对症支持治疗可以提高患者生存率。为了应对未来可能的疫情暴发,防患于未然,本文对马尔堡病毒病的病毒学、病理特征、临床表现、诊断学、抗病毒药物、疫苗研发和防控策略等方面进行了全面综述,旨在提高我国医务人员对该病的认识,为未来潜在的疫情暴发防治工作提供直接或间接的理论和实践参考。

关键词: 马尔堡病毒病, 病理特征, 临床表现, 抗病毒药物, 疫苗研发

Abstract: Since its first discovery during outbreaks in Marburg, Germany, Frankfurt, and Yugoslavia in 1967, the Marburg virus disease has caused multiple high-fatality epidemics on various continents, primarily concentrated in sub-Saharan Africa. Belonging to the Filoviridae family, the virus often leads to severe hemorrhagic fever in infected individuals, followed by organ failure and death. The Marburg virus disease can be transmitted person-to-person in household or healthcare settings. Currently, there are no effective preventive or therapeutic measures available. However, systematic supportive care can improve survival rates. In order to proactively address potential future outbreaks, this article provides a comprehensive review of the virology, pathological features, clinical manifestations, diagnostics, antiviral drugs, vaccine development, and preventative strategy of the Marburg virus disease. The aim is to enhance the understanding of healthcare professionals in China regarding this virus and provide direct or indirect theoretical and practical references for future prevention and control efforts against potential outbreaks.

Key words: Marburg virus disease, Pathological features, Clinical manifestations, Antiviral drugs, Vaccine development

中图分类号:

R511

姚伟明, 王福祥, 张培燕, 卢洪洲. 马尔堡病毒病的研究进展[J]. 新发传染病电子杂志, 2025, 10(1): 77-81.

Yao Weiming, Wang Fuxiang, Zhang Peiyan, Lu Hongzhou. Research progress on Marburg virus disease[J]. Electronic Journal of Emerging Infectious Diseases, 2025, 10(1): 77-81.

参考文献

[1] KORTEPETER MG, DIERBERG K, SHENOY ES, et al.Marburg virus disease: A summary for clinicians[J].Int J Infect Dis, 2020, 99: 233-242.
[2] BRAUBURGER K, HUME AJ, MUHLBERGER E, et al.Forty-five years of Marburg virus research[J].Viruses, 2012, 4(10): 1878-1927.
[3] WHO. Ebola and Marburg virus disease epidemics: preparedness, alert, control, and evaluation[EB/OL].[2024-08-06].https://www.who.int/publications/i/item/ebola-and-marburg-virus-disease-epidemics-preparedness-alert-control-and-evaluation.
[4] UWISHEMA O.First Marburg virus outbreak in Rwanda: urgent actions needed[J].Lancet, 2024, 404(10463): 1639.
[5] CUOMO-DANNENBURG G, MCCAIN K, MCCABE R, et al.Marburg virus disease outbreaks, mathematical models, and disease parameters: a systematic review[J].Lancet Infect Dis, 2024, 24(5): e307-e317.
[6] JANUS BM, WANG R, CLEVELAND TE 4TH, et al. Macaque antibodies targeting Marburg virus glycoprotein induced by multivalent immunization[J].J Virol, 2024, 98(7): e0015524.
[7] GUITO JC, KIREJCZYK SGM, SCHUH AJ, et al.Coordinated inflammatory responses dictate Marburg virus control by reservoir bats[J].Nat Commun, 2024, 15(1): 1826.
[8] SHIFFLETT K, MARZI A.Marburg virus pathogenesis - differences and similarities in humans and animal models[J].Virol J, 2019, 16(1): 165.
[9] HOFFMANN M, CRONE L, DIETZEL E, et al.A polymorphism within the internal fusion loop of the Ebola virus glycoprotein modulates host cell entry[J].J Virol, 2017, 91(9): 1-14.
[10] CROSS RW, MIRE CE, FELDMANN H, et al.Post-exposure treatments for Ebola and Marburg virus infections[J].Nat Rev Drug Discov, 2018, 17(6): 413-434.
[11] BORCHERT M, MULANGU S, SWANEPOEL R, et al.Serosurvey on household contacts of Marburg hemorrhagic fever patients[J].Emerg Infect Dis, 2006, 12(3): 433-439.
[12] BAUER MP, TIMEN A, VOSSEN ACTM, et al.Marburg haemorrhagic fever in returning travellers: an overview aimed at clinicians[J].Clin Microbiol Infect, 2019, 21S: e28-e31.
[13] WHO. Marburg virus disease[EB/OL].[2024-10-23].https://www.who.int/news-room/fact-sheets/detail/marburg-virus-disease.
[14] BIXLER SL, BOCAN TM, WELLS J, et al.Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus[J].Antiviral Res, 2018, 151: 97-104.
[15] PORTER DP, WEIDNER JM, GOMBA L, et al.Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus[J].J Infect Dis, 2020, 222(11): 1894-1901.
[16] DIAZ AM, SMITH LM, PETERSON AN, et al.Impact of Pharmacist Inhaler Prescribing at Discharge for Chronic Obstructive Pulmonary Disease on Readmission Rates[J].Chronic Obstr Pulm Dis, 2025, 12(1): 43-51.
[17] DYE JM, HERBERT AS, KUEHNE AI, et al.Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease[J].Proc Natl Acad Sci USA, 2012, 109(13): 5034-5039.
[18] MIRE CE, GEISBERT JB, BORISEVICH V, et al. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody[J].Sci Transl Med, 2017, 9(384): eaai8711.
[19] URSIC-BEDOYA R, MIRE CE, ROBBINS M, et al.Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA[J].J Infect Dis, 2014, 209(4): 562-570.
[20] THI EP, MIRE CE, URSIC-BEDOYA R, et al. Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA[J].Sci Transl Med, 2014, 6(250): 250ra116.
[21] WOOLSEY C, GEISBERT JB, MATASSOV D, et al.Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates[J].J Infect Dis, 2018, 218(suppl_5): S582-S587.
[22] CALLAWAY E.Deadly Marburg virus: scientists race to test vaccines in outbreak[J].Nature, 2024, 634(8033): 278.
[23] REYNOLDS P, MARZI A.Ebola and Marburg virus vaccines[J].Virus Genes, 2017, 53(4): 501-515.
[24] SUSCHAK JJ, SCHMALJOHN CS.Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates[J].Hum Vaccin Immunother, 2019, 15(10): 2359-2377.
[25] ALLA D, PARUCHURI SSH, TIWARI A, et al.The mortality, modes of infection, diagnostic tests, and treatments of Marburg virus disease: A systematic review[J].Health Sci Rep, 2023, 6(9): e1545.
[26] KARAMI H, LETAFATI A, FAKHR SSH.Can Marburg virus be sexually transmitted?[J].Health Sci Rep, 2024, 7(8): e2270.
[27] KUMING BS, KOKORIS N.Uveal involvement in Marburg virus disease[J].Br J Ophthalmol, 1977, 61(4): 265-266.

马尔堡病毒病的研究进展

Research progress on Marburg virus disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价

[1]	高兴娟, 程磊, 马秀清, 刘守珠, 王宝英, 刘海燕, 才德吉, 杨兴唐. 慢性丙型肝炎基因1型患者抗病毒治疗对丙型肝炎病毒核心抗原、肝脂肪变性和纤维化的影响[J]. 新发传染病电子杂志, 2024, 9(6): 54-59.
[2]	王丽萍, 张月, 孙滨州, 王岩岩. 120例女性宫颈病变患者HPV感染的基因型分布和病理特征分析[J]. 新发传染病电子杂志, 2024, 9(4): 23-28.
[3]	范萌, 尹训涛, 刘光明, 胡悦林. 儿童脓肿型与非脓肿型颈部感染性肿块的临床及影像特征分析[J]. 新发传染病电子杂志, 2024, 9(2): 1-6.
[4]	姚伟明, 王福祥, 卢洪洲. 尼帕病毒的最新研究进展[J]. 新发传染病电子杂志, 2024, 9(1): 60-66.
[5]	谢东胜, 邓国防, 韩婷婷. 先天性结核病的诊治进展[J]. 新发传染病电子杂志, 2023, 8(3): 74-78.
[6]	黄丽萍, 陆艾丽, 彭劼. 非HIV马尔尼菲篮状菌病的研究进展[J]. 新发传染病电子杂志, 2022, 7(2): 89-94.
[7]	郑祎, 王辉. 艾滋病合并马尔尼菲篮状菌感染的诊治临床研究进展[J]. 新发传染病电子杂志, 2021, 6(2): 151-154.
[8]	张复春, 赵令斋. 寨卡病毒病的临床相关研究现状及挑战[J]. 新发传染病电子杂志, 2016, 1(1): 1-5.